MC10 Inc. and the Shirley Ryan AbilityLab have announced a partnership in novel neurodegenerative- and motion-related disability therapy development.
Shirley Ryan AbilityLab will use MC10’s BioStampRC, a wearable sensor system that captures physiological data, in clinical research studies. The goal of the collaboration is to determine how the sensor system can be used in clinical and home environments in the rehabilitation process, according to a press release.
“… We look forward to developing new therapies and solutions with BioStamp RC sensors, furthering our goal of improving treatment and recovery, and of advancing human ability,” David Zembower, PhD, executive director of innovation and clinical research at Shirley Ryan AbilityLab, said in the release.
Injuries that result in motion/biomechanics-related disabilities, including stroke, traumatic brain injury, incomplete spinal cord injury and neurodegenerative diseases, will be the initial areas of research. Outcomes will be reported in publications and at conferences, according to the release.
“MC10 is dedicated to improving health care with digital solutions,” Scott Pomerantz, chief executive officer of MC10, said in the release. “By collaborating with the Shirley Ryan AbilityLab … we’re positioning our technology to make a real, positive impact on human health.”
References:
